ObsEva SA to Participate in JP Morgan Healthcare Conference January 8 - 11, 2018

Geneva, Switzerland and Boston, MA - January 5, 2018- ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that company management will participate in JP Morgan's 36th Annual Healthcare Conference being held from January 8-11, 2018 in San Francisco. 

ObsEva's presentation will take place on Thursday, January 11 at 8 a.m. Pacific Time (PT).  A webcast will be available in the "Investors" section of ObsEva's website www.ObsEva.com.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.

Media Contact:

Liz Bryan
Spectrum Science
lbryan@spectrumscience.com
202-955-6222 x2526

CEO Office contact:

Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact

Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
781-366-5726

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/c5d0fcf7-167f-4b83-b660-893da2f380b1